Skip to main content
. 2021 Sep 16;9(9):1230. doi: 10.3390/biomedicines9091230

Figure 1.

Figure 1

EV inhibitors for screening as anti-SARS-CoV-2 agents in this study. (a) Exosome production and release inhibitors. (b) Microvesicle generation inhibitors. Targets and mechanism of action (MOA) of these compounds are provided in Supplementary Materials Table S1.